Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

746 - Tumor-infiltrating lymphocytes and pathologic complete response among the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) : Single center experience


24 Nov 2018


Poster display - Cocktail


Cytotoxic Therapy;  Targeted Therapy;  Pathology/Molecular Biology

Tumour Site

Breast Cancer


Jooyoung Ha


Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427


J. Ha1, J.E. Kim1, J.H. Jeong1, J. Ahn1, K.H. Jung1, H.J. Lee2, G. Gong2, E.Y. Chae3, H.H. Kim3, I.Y. Chung4, B.S. Ko4, S. Kim1

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Department Of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 3 Department Of Radiology And Research Institute Of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 4 Department Of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR

Abstract 746


Pathologic complete response (pCR) is known to be a predictive marker for favorable outcome after neoadjuvant treatment in HER2 positive (+) breast cancer. Our aim was to investigate the association between hormone receptor (HR) or tumor-infiltrating lymphocytes (TILs) and pCR in HER2 (+) breast cancer treated with dual anti-HER2 therapy.


Ninety-four patients with HER2 (+) breast cancer who received neoadjuvant treatment with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) were included in this retrospective analysis. Associations between TILs and pCR were assessed in the overall and hormone receptor (HR) positive (+) and HR negative (-) populations. We classified subgroups with a cutoff value of stromal TILs (≤20% TILs vs > 20% TILs) based on ROC curves.


Of the 94 cases, 54 (57.4%) tumors achieved pCR (ypT0/is N0) and median TILs was 17.07% [13.81-20.65]. In analysis of hormone receptor, pCR was 51.0% (n = 26/51) in HR (+) group and 65.1% (n = 28/43) in HR (-) group (p = 0.167). The pCR rate was higher in the high TILs group than in the low TILs group (74.1% vs 51.4%, p = 0.038). In HR (-) group, high TILs and low TILs achieved 90% (n = 9/10) and 57.6% (n = 19/33) of pCR, respectively. In HR (+), pCR rates of high TILs and low TILs subgroups were 64.7% (n = 11/17) and 41.7% (n = 15/34).


In HER2 (+) breast cancer, HR (-) and high TILs showed higher pCR compared with HR(+) and low TILs. TILs might be a predictive marker for the treatment response to neoadjuvant dual anti HER2 based chemotherapy. Further investigation in a larger cohort of samples is needed to validate these results.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.